Harrow, Inc. (HROW)

In the past six months, Harrow, Inc. stock has been impacted by the report of its Fourth Quarter and Third Quarter 2025 earnings. The company announced it would report its First Quarter 2026 financial results after market close on May 11, 2026. The Centers for Medicare & Medicaid Services announced a permanent J-Code for IOPIDINE® 1%, effective July 1, 2026, which is expected to support broader adoption. The FDA cleared an Investigational New Drug (IND) application to support a planned Phase 3 clinical trial for TRIESENCE®. HROW shares increased by 64.50% over the year leading up to April 22, 2026, but decreased by 22.0% since the start of 2026 as of May 8, 2026. There were reports of major investor activity, including Opaleye Management Inc. selling shares in June 2025 and another major investor selling $7.8 million in Harrow stock in March 2026. The stock experienced a 35% pullback after conservative 2026 guidance following Q4 2025 earnings.

Demand for Harrow, Inc.'s products and services exhibits seasonality. Management anticipates a softer first half of the year due to factors such as stocking drawdown, deductible dynamics, and transitions in Ambulatory Surgical Centers (ASCs). The majority of the company's EBITDA and revenue acceleration are expected in the second half of the year. The first quarter typically sees a seasonal decline, and the third quarter has also been noted as seasonally slower, with demand rebounding in September.

Harrow, Inc. is an eyecare pharmaceutical company focused on the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. The company operates within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Harrow's business model is built around FDA-approved branded pharmaceuticals, high-quality compounded formulations sold under its ImprimisRx brand, and minority equity stakes in emerging ophthalmic innovators. Its major products include ophthalmic solutions addressing various eye conditions, such as IHEEZO™, VEVYE®, and TRIESENCE®, as well as other notable products and a development pipeline including candidates like MELT-300, H-N08, CR-01, and MELT-210.

Harrow, Inc. primarily focuses its commercial operations on the United States market, with its corporate headquarters located in Nashville, Tennessee. The company has a commercial infrastructure that reaches over 10,000 eye care professionals in the U.S. market. Harrow holds global patent protection for MELT-300 across North America, Europe, Asia, Australia, and the Middle East, with plans to license ex-U.S. rights to regional partners.

Harrow, Inc. generally maintains a positive brand reputation as a leading provider of ophthalmic disease management solutions in North America and one of the fastest-growing ophthalmic pharmaceutical companies in the United States. The company prides itself on innovation and providing affordable and accessible medications. However, the company has faced some reputation challenges, including criticisms of management being overly promotional and failing to consistently live up to lofty promises, as well as controversies related to its compounding pharmacy business in its early history. The company's current strategy emphasizes FDA-approved branded pharmaceuticals and a disciplined acquisition approach.

Harrow, Inc. has a mix of institutional and individual ownership. As of April 9, 2026, there were 218 institutional owners and shareholders holding a total of 22,204,776 shares. Major institutional owners include Opaleye Management Inc., BlackRock, Inc., and Vanguard Group Inc. Key individual owners, who are also insiders, include Mark L. Baum, Robert J. Kammer, and Alexej Ladonnikov. Institutional shareholders collectively hold 59.59% of Harrow stock, while insiders hold 140.70%.